Delcath Q2 Growth Drives Higher HEPZATO Sales and Raised 2026 Guidance
Delcath Systems reported second-quarter revenue of $29.1 million, up from $24.2 million, driven by HEPZATO KIT sales of $27.1 million and additional CHEMOSAT revenue. Gross margin rose to 90% as the business scaled, and the company raised 2026 guidance to $104–$108 million. Cash and investments totaled $95.9 million with no debt, though SG&A increased to $13.4 million.